|Articles|June 21, 2023
AAV Manufacturing: The benefits of growing serum-free, suspension HEK293 cells in the scale-X™ fixed-bed bioreactor
Author(s)Univercells Technologies
In this study, HEK293F cells grown in scale-X bioreactor produce >3x higher AAV-2 vector, with 25-52% lower cost than the reference process.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
2
FAQ: What You Need to Know About How Industry is Tackling CGT Bottlenecks
3
BioPharm Weekly News Roundup—Week of Nov. 24, 2025
4
Drug Digest: Biopharma Landscape Evolves Through Strategic Alliances and Technology Integration
5
